Tezepelumab is a humanized IgG2λ mAb that inhibits thymic stromal lymphopoietin (TSLP), an airway epithelial cytokine [12,20], and it has shown a wider therapeutic action in both type 2 high and low severe asthma patients [38]. This evidence concerns the gene TSLP and asthma.